AmCad BioMed Corporation
Exhibitor
Information
AmCad BioMed, founded in 2008 and listed on the Taipei Exchange (Ticker: 4188), specializes in AI-powered ultrasound solutions that support early and accurate diagnosis.
We develop patented ultrasound AI technologies that help doctors detect diseases faster and interpret images with greater consistency.
Headquartered in Taiwan, AmCad holds multiple FDA and CE certifications and continues to advance medical imaging through real-world innovation.
We are committed to responsible growth, with strong investments in R&D and a focus on ESG principles across our operations.
Nature of Business
Manufacturer
Country
Taiwan (Province of China)
Hall Numbers
South Hall 7
Imaging
Diagnostic and Therapy/Ultrasound Machines
IT Systems, Solutions & Digital Health
Digital Health and Artificial Intelligence / Artificial Intelligence
